Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 654

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Homologous and Heterologous Covid-19 Booster Vaccinations

Open access
Atmar, Robert L., Lyke, Kirsten E., Deming, Meagan E., Jackson, Lisa A., Branche, Angela R., El Sahly, Hana M., Rostad, Christina A., Martin, Judith M., Johnston, Christine, Rupp, Richard E., Mulligan, Mark J., Brady, Rebecca C., Frenck, Robert W., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Rajakumar, Kumaravel, Edupuganti, Srilatha, Dobrzynski, David, Coler, Rhea N., Posavad, Christine M., Archer, Janet I., Crandon, Sonja, Nayak, Seema U., Szydlo, Daniel, Zemanek, Jillian A., Dominguez Islas, Clara P., Brown, Elizabeth R., Suthar, Mehul S., McElrath, M. Juliana, McDermott, Adrian B., O’Connell, Sarah E., Montefiori, David C., Eaton, Amanda, Neuzil, Kathleen M., Stephens, David S., Roberts, Paul C., Beigel, John H.·2022·New England Journal of Medicine

Abstract

ABSTRACT Background While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen. Methods In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×10 10 virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29. Results 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations. Conclusion Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by National Institute of Allergy and Infectious Diseases; Clinical Trials.gov number, NCT04889209 )

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2116414

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 654

Metadata

Authors
Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., Coler, R. N., Posavad, C. M., Archer, J. I., Crandon, S., Nayak, S. U., Szydlo, D., Zemanek, J. A., Dominguez Islas, C. P., Brown, E. R., Suthar, M. S., McElrath, M. J., McDermott, A. B., O’Connell, S. E., Montefiori, D. C., Eaton, A., Neuzil, K. M., Stephens, D. S., Roberts, P. C., & Beigel, J. H.
Venue
New England Journal of Medicine
Published
2022-03-17
Volume
386
Issue
11
Pages
1046-1057
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4210450230
Cited by
654
References
36
FWCI
68.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Homologous and Heterologous Covid-19 Booster Vaccinations. https://app.cochat.ai/papers/10.1056/nejmoa2116414
The paper
Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., . . . Beigel, J. H. (2022). Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2116414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.